Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

LBL 007

X
Drug Profile

LBL 007

Alternative Names: LBL-007; LBL-007 injection

Latest Information Update: 27 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Leads Biolabs
  • Developer BeiGene; Leads Biolabs
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD223 antigen inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer; Oesophageal cancer; Squamous cell cancer
  • Phase I/II Colorectal cancer; Solid tumours
  • No development reported Lymphoma; Malignant melanoma

Most Recent Events

  • 08 Nov 2023 Phase-II clinical trials in Oesophageal cancer (Combination therapy, First-line therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in South Korea, China (IV) (NCT06010303)
  • 08 Nov 2023 Phase-II clinical trials in Squamous cell cancer (First-line therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Combination therapy) in South Korea, China (IV) (NCT06010303)
  • 24 Aug 2023 BeiGene plans phase II trial in Squamous cell cancer and Oesophageal cancer (First-line therapy, Metastatic disease, Late-stage disease and Combination therapy) in November 2023 (IV) (NCT06010303)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top